WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 9, 431-435. Review Article ISSN 2277–7105

BRAIN STEM CELL TUMORS: PATHOPHYSIOLOGY, CURRENT THERAPEUTIC APPROACHES, AND EMERGING STRATEGIES IN NEURO-ONCOLOGY

Dr. Sahukar[1]*, Mr. Juber Khan[2], Mr. Samsad Khan[3], Mr. Rahul Khan[4]

[1]M. Pharma (Pharmacology), Ph. D, Associate Professor, Alwar Pharmacy College, Alwar, Rajasthan.

[2,3]M. Pharma (Pharmacology) Assistant Professor Alwar Pharmacy College, Alwar, Rajasthan.

[4]M. Pharma (Pharmaceutics) Assistant Professor Alwar Pharmacy College, Alwar, Rajasthan.

Article Received on 31 March 2026,
Article Revised on 21 April 2026,
Article Published on 01 May 2026

https://doi.org/10.5281/zenodo.19875175

***Corresponding Author**

Dr. Sahukar

M. Pharma (Pharmacology), Ph. D, Associate Professor, Alwar Pharmacy College, Alwar, Rajasthan.

How to cite this Article: Dr. Sahukar[1]*, Mr. Juber Khan[2], Mr. Samsad Khan[3], Mr. Rahul Khan[4] (2026). Brain Stem Cell Tumors: Pathophysiology, Current Therapeutic Approaches, and Emerging Strategies in Neuro-Oncology. World Journal of Pharmaceutical Research, 15(9), 431–435.

ABSTRACT

Brain stem cell tumors are among the most aggressive and fatal malignancies of the central nervous system (CNS). These tumors arise predominantly in the brainstem region, often affecting children and young adults, with poor prognosis due to their infiltrative nature, critical anatomical location, and resistance to conventional therapies. The pathogenesis involves genetic mutations, dysregulation of signaling pathways, and aberrant neural stem cell activity, which collectively drive uncontrolled tumor growth. Current treatment modalities, including surgery, radiotherapy, and chemotherapy, remain largely palliative, as complete resection is frequently impossible and therapeutic resistance is common. Recent advances in stem cell biology, targeted molecular therapies, immunotherapy, nanotechnology-based drug delivery, and the exploration of natural/herbal compounds with neuroprotective potential have opened new avenues for research. This review provides an updated overview of the pathophysiology, current treatment options, and future therapeutic perspectives for brain stem cell tumors, emphasizing the challenges and opportunities in developing effective neuro-oncological interventions.

KEYWORDS: Brain stem cell tumor, glioma, neuro-oncology, stem cells, targeted therapy, immunotherapy, nanotechnology, herbal medicine.

1. INTRODUCTION

Brain tumors constitute a heterogeneous group of malignancies that significantly contribute to morbidity and mortality worldwide. Among them, brain stem cell tumors, particularly diffuse intrinsic pontine gliomas (DIPGs), represent one of the most challenging entities in neuro-oncology. The brainstem, composed of the midbrain, pons, and medulla oblongata, is responsible for critical life-sustaining functions such as respiration, cardiovascular regulation, and motor coordination. Tumors in this region are often inoperable due to their location and infiltrative behavior, making them highly lethal.

Epidemiological studies suggest that brainstem gliomas account for nearly 10–20% of all pediatric brain tumors, with the majority being diagnosed in children between 5 and 10 years of age. In adults, the incidence is comparatively lower but associated with equally poor outcomes. Despite significant progress in molecular oncology, the prognosis of brain stem tumors remains grim, with median survival often less than one year for aggressive subtypes such as DIPG.

Given the limitations of conventional therapies, there is a growing need to explore novel approaches that integrate stem cell biology, targeted molecular therapies, immunotherapy, and alternative neuroprotective agents. This review highlights the pathophysiology, current treatment options, and future perspectives in the management of brain stem cell tumors.

2. Epidemiology and Classification

Brain stem tumors are rare but disproportionately lethal. They can be classified based on histopathology, molecular genetics, and clinical behavior.

- Diffuse Intrinsic Pontine Glioma (DIPG): Most common malignant brainstem tumor in children; highly infiltrative and resistant to therapy.
- Focal Brainstem Gliomas: More localized, potentially resectable, and associated with better prognosis.
- Exophytic Tumors: Extend outward from the brainstem and may be surgically accessible.
- Molecular Subtypes: Mutations in H3K27M, TP53, IDH1/2, PDGFRA, and EGFR play critical roles in tumor development.

The World Health Organization (WHO) has integrated molecular markers into the classification of CNS tumors, highlighting the role of genetic mutations in diagnosis and prognosis.

3. Pathophysiology and Molecular Mechanisms

Brain stem cell tumors arise from aberrant neural stem cells and glial progenitor cells located within the brainstem. These tumors exhibit aggressive biological behavior due to a combination of genetic, epigenetic, and microenvironmental factors.

3.1 Genetic Alterations

-Histone Mutations (H3K27M): One of the hallmark mutations in DIPG.
-TP53 Mutations: Contribute to genomic instability and apoptosis resistance.
-EGFR Amplification & PDGFRA Mutations: Drive aberrant growth factor signaling.
-IDH1/2 Mutations: Rare in pediatric cases but associated with metabolic alterations.

3.2 Epigenetic Dysregulation

- Abnormal methylation patterns and histone modifications alter transcriptional regulation.

3.3 Stem Cell Niche and Tumor Microenvironment

-Neural stem cells in the subventricular zone may act as tumor-initiating cells.
-Hypoxia upregulates HIF-1α, promoting angiogenesis and progression.

3.4 Mechanisms of Resistance

-Blood–Brain Barrier limits drug penetration.
-Cancer Stem Cell Population survives therapy, leading to relapse.
-Signaling pathways like PI3K/AKT/mTOR, MAPK/ERK, Notch aid survival.

4. Current Therapeutic Approaches

Despite decades of research, the treatment of brain stem cell tumors remains highly challenging.

4.1 Surgery

-Limited by critical anatomy, mostly diagnostic.

4.2 Radiotherapy

-Standard of care for DIPG, modest extension of survival.

4.3 Chemotherapy

- Temozolomide, Bevacizumab, and combination regimens tested with limited efficacy.

4.4 Targeted Therapies

- Tyrosine kinase inhibitors, mTOR inhibitors, and HDAC inhibitors.

4.5 Limitations

- Poor drug penetration, high recurrence, neurotoxicity.

5. Novel and Emerging Therapies

5.1 Stem Cell–Based Therapy

-Neural and mesenchymal stem cells for drug and gene delivery.

5.2 Nanotechnology-Based Drug Delivery

- Liposomes, nanoparticles, magnetic nanocarriers, dendrimers.

5.3 Immunotherapy

- Checkpoint inhibitors, CAR-T cells, vaccines, oncolytic viruses.

5.4 Gene Therapy

- Suicide genes, CRISPR/Cas9 editing.

5.5 Herbal and Natural Compounds

- Curcumin, resveratrol, withaferin A, EGCG.
- Require nanoformulations for BBB penetration.

6. Challenges and Limitations

- Inoperability due to anatomy.
- Drug resistance.
- Severe toxicity.
- Limited clinical trials.
- Blood–Brain Barrier restriction.

7. Future Directions

- Integration of multi-omics for precision medicine.
- Combination therapies (immunotherapy + nanotech).
- Biodegradable nanocarriers.
- Herbal compounds as adjuncts.

- CRISPR-based editing.

8. CONCLUSION

Brain stem cell tumors remain among the deadliest malignancies in neuro-oncology. Conventional therapies offer limited survival benefit due to tumor location, infiltrative behavior, and therapeutic resistance. Recent advances in stem cell–based approaches, nanotechnology, immunotherapy, and natural neuroprotective compounds provide hope for the development of effective, targeted, and less toxic therapies. Future research must focus on translational strategies to improve patient outcomes.

9. REFERENCES

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system. Neuro Oncol, 2021; 23(8): 1231-1251.
2. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines distinct subgroups of pediatric gliomas. Acta Neuropathol, 2012; 124(3): 439–447.
3. Stupp R, Hegi ME, Mason WP, et al. Radiotherapy with concomitant and adjuvant temozolomide in glioblastoma. N. Engl. J. Med., 2005; 352(10): 987–996.
4. Majd N, Carceller F, Alonso MM, et al. Oncolytic virotherapy for diffuse intrinsic pontine glioma. Expert Opin. Biol. Ther., 2021; 21(1): 67–80.
5. Venkatesh HS, Monje M. Neuronal activity in ontogeny and oncology. Trends Cancer, 2017; 3(2): 89–112.